Content :

Sitemap

• Our vision
  • Message from Senior management
  • The Group's profile
  • Our CSR Approach
    • Strategy and approach
    • CSR governance
    • CSR networks
    • CSR initiatives
    • CSR Awards
  • Our report overview
    • Materiality test
      • Materiality analysis process
      • Materiality analysis results
    • The Business Case Approach
  • Our Stakeholders
  • Policies and management systems
    • Internal policies
    • Management systems
      • Standards and controls
      • HSE
      • Quality
      • Pharmacovigilance
      • Compliance
      • Internal audit
    • Risk management
      • Managing risks
      • Risk factors
      • Our challenges
      • Protecting against risks
  • Standards and memberships
    • Complying with standards
    • Memberships and partnerships
  • CSR performance
    • GRI
    • Recognition and awards
      • Statutory auditors’ report
    • Methodological note
    • Statutory auditors’ report
    • Social indicators
    • Environmental indicators
    • Other indicators
• Patient
  • Patient Indicators
  • Access to healthcare
    • The Group's commitment
      • Background
      • Challenges
      • Policy
      • Our investments and programs
    • Infectious diseases
      • Malaria
      • Neglected tropical diseases
      • Tuberculosis
      • Access to vaccines
      • Polio
      • Yellow fever
      • Influenza
    • Non-communicable diseases
      • Oncology
      • Diabetes
      • Epilepsy and mental illness
      • Our affiliates’ achievements
    • Rare diseases
      • Actions
    • Humanitarian emergencies
      • Actions
  • Supporting patients and their families
    • Policy
    • Actions
    • Transparency
  • Innovation for patients
    • Managing innovation
      • Innovation management structures
      • Internal initiatives to foster a culture of innovation
    • Our innovations in 2011
      • Innovations in industrial processes
      • New services for patients
      • Innovative acquisitions, partnerships, and other business ventures
      • Innovative products
    • Business Case: Valuable progress in dengue fever vaccine program in 2011
    • Business Case: The aging patient
    • External recognition
  • Product risk management
    • Pharmacovigilance
      • Policy
      • Actions
      • Business case
    • Global quality
      • Actions
    • Continuity of activities and supplies
      • Policy
      • Actions
      • Business case
    • The fight against counterfeit drugs
      • Policy
      • Actions
• Ethics
  • Ethics Indicators
  • Ensuring Respect of Human Rights
    • Policy
    • Actions
    • Business Case
  • Ethics in R&D
    • Ethics in clinical trials
      • Policy
      • Actions
      • Business case
    • Bioethics
      • Actions
    • Use of laboratory animals for research
      • Policy
      • Actions
      • Indicators
    • Nanotechnology
      • Actions
  • Business ethics
    • Governance
      • Actions
    • Prevention of conflicts of interest
    • Responsible Lobbying
      • Actions
    • Fighting corruption
      • Policy
      • Actions
    • Respect for free competition
    • Supply Chain
    • Responsible marketing
      • General policy
      • Pharmaceutical marketing practices
      • Training for medical sales representatives
      • Distribution of samples
      • Conferences and physicians’ meetings
    • Personal data protection
      • About informed consent
      • Actions
      • Business case: Ethics
    • Responsible procurement
      • Actions
      • Indicators
      • Business Case
• People
  • People Indicators
  • Diversity
    • Preventing discrimination / Promoting Diversity
      • Policy
      • Actions
    • Gender balance
      • Policy
      • Actions
      • Statistics
    • Disability
      • Policy
      • Actions
    • Supporting all generations
    • Other diversity topics
  • Supporting change
    • Actions
  • Workforce development
    • Actions
    • Business Case
  • Relationships with schools and universities
    • Actions
  • Compensation and employee benefits
    • Compensation
    • Employee benefits
    • Work-life balance
      • Actions
    • Supporting employees children
      • Actions
    • Business case: Compensation Employee benefits
  • Employee representation and information
    • Actions
  • Health and Safety
    • Safety in the workplace
      • Actions
      • Indicators
      • Business case: Health Safety
    • Occupational health
      • Actions
      • Indicators
    • HSE compliance for subcontractors and suppliers
      • Actions
  • Local Economic Development
    • Actions
    • Indicators
  • Employee volunteering
    • Actions
    • Worldmap
• Planet
  • Planet Indicators
  • Energy and carbon footprint
    • Background
    • Policy
    • Actions
    • Indicators
    • Business case
  • Local environmental impact
    • Green chemistry
      • Actions
      • Business Case
    • Water management
      • Policy
      • Actions
      • Indicators
      • Business case
    • Protection of the atmosphere
      • Policy
      • Actions
      • Indicators
    • Packaging
      • Business case
    • Waste management
      • Policy
      • Actions
      • Indicators
    • Soil and groundwater protection
  • Pharmaceuticals in the environment
    • Actions
  • Biodiversity
    • Policy
      • Position Paper
    • Actions
      • Natural substances
      • Preserving biodiversity at our sites and beyond
      • Safeguarding against biopiracy
    • Business case